Literature DB >> 28442265

Downregulation of β-arrestin 1 suppresses glioblastoma cell malignant progression vis inhibition of Src signaling.

Tian Lan1, Haoran Wang2, Zhihua Zhang1, Mingshan Zhang2, Yanming Qu2, Zitong Zhao3, Xinyi Fan3, Qimin Zhan4, Yongmei Song5, Chunjiang Yu6.   

Abstract

Glioblastoma multiforme (GBM) is one of the most common brain malignancies worldwide and is typically associated with a dismal prognosis, yet the mechanisms underlying its aggressiveness remain unclear. Here, we revealed that β-arrestin 1 was overexpressed in GBM and contributed to poorer outcome. Knockdown of β-arrestin 1 suppressed the proliferation, invasiveness and glycolysis of GBM cells, and also enhanced temozolomide efficacy. Further, we discovered that knockdown of β-arrestin 1 decreased the activity of Src, and suppression of Src signaling was critically involved in β-arrestin 1 silencing-mediated suppression of GBM malignancies. Finally, we investigated the effect of β-arrestin 1 knockdown on the tumor growth and survival of xenograft models, and found that shβ-arrestin 1 apparently inhibited GBM growth in vivo and resulted in better survival of mice. Taken together, our findings suggest that knockdown of β-arrestin 1 can suppress GBM cell proliferation, invasion and glycolysis by inhibiting Src signaling. Thus, targeting β-arrestin 1 may be a potential therapeutic strategy for GBM treatment.
Copyright © 2017. Published by Elsevier Inc.

Entities:  

Keywords:  Cell growth; GBM; Glycolysis; Invasion; Src; β-arrestin 1

Mesh:

Substances:

Year:  2017        PMID: 28442265     DOI: 10.1016/j.yexcr.2017.04.023

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  9 in total

1.  Combination of pembrolizumab and 125I attenuates the aggressiveness of non-small cell lung cancer.

Authors:  Shuo Wang; Jun Zhang; Fan-Jie Meng; Yi-Jie Yan; Bin Wang; Zhi-Yu Guan
Journal:  Oncol Lett       Date:  2020-04-03       Impact factor: 2.967

2.  β-Arrestins Regulate Stem Cell-Like Phenotype and Response to Chemotherapy in Bladder Cancer.

Authors:  Georgios Kallifatidis; Diandra K Smith; Daley S Morera; Jie Gao; Martin J Hennig; James J Hoy; Richard F Pearce; Isha R Dabke; Jiemin Li; Axel S Merseburger; Markus A Kuczyk; Vinata B Lokeshwar; Bal L Lokeshwar
Journal:  Mol Cancer Ther       Date:  2019-02-20       Impact factor: 6.261

3.  Reciprocal control of ADAM17/EGFR/Akt signaling and miR-145 drives GBM invasiveness.

Authors:  Yuduo Guo; Xin He; Mingshan Zhang; Yanming Qu; Chunyu Gu; Ming Ren; Haoran Wang; Weihai Ning; Junfa Li; Chunjiang Yu; Hongwei Zhang
Journal:  J Neurooncol       Date:  2020-03-13       Impact factor: 4.130

Review 4.  The role and mechanism of β‑arrestins in cancer invasion and metastasis (Review).

Authors:  Qing Song; Qing Ji; Qi Li
Journal:  Int J Mol Med       Date:  2017-11-27       Impact factor: 4.101

5.  ARRB1 Drives Gallbladder Cancer Progression by Facilitating TAK1/MAPK Signaling Activation.

Authors:  Xudong Zhang; Zhijun Kong; Xiaoliang Xu; Xiao Yun; Jiadeng Chao; Dong Ding; Tao Li; Yuan Gao; Naifu Guan; Chunfu Zhu; Xihu Qin
Journal:  J Cancer       Date:  2021-01-30       Impact factor: 4.207

6.  RNF12 Promotes Glioblastoma Malignant Proliferation via Destructing RB1 and Regulating MAPK Pathway.

Authors:  Eryi Sun; Ping Zhang
Journal:  J Healthc Eng       Date:  2021-11-30       Impact factor: 2.682

Review 7.  Small Molecule Inhibitors in Adult High-Grade Glioma: From the Past to the Future.

Authors:  Wenda Huang; Zhaonian Hao; Feng Mao; Dongsheng Guo
Journal:  Front Oncol       Date:  2022-06-17       Impact factor: 5.738

8.  The Role of β-Arrestin1 in Esophageal Squamous Cell Carcinoma.

Authors:  Zhijie Tan; Bin Li; Xia Dong; Wenxing Liu; Shanshan Liu
Journal:  Onco Targets Ther       Date:  2020-03-03       Impact factor: 4.147

9.  miR‑379‑5p inhibits cell proliferation and promotes cell apoptosis in non‑small cell lung cancer by targeting β‑arrestin‑1.

Authors:  Yonghong Jiang; Panpan Zhu; Yamei Gao; Aiping Wang
Journal:  Mol Med Rep       Date:  2020-09-30       Impact factor: 2.952

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.